Radiation plus drug combo for kidney cancer that has spread a little
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of kidney cancer called clear cell renal cell carcinoma.
- You are 18 years or older.
- You have up to 5 places where the cancer has spread, and each can be treated with radiation.
- You either have not had drug treatment for the spread, or you've had only one type of targeted drug (TKI) and the spread is limited.
- Your overall health is reasonably good, as determined by a standard score.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial tests whether adding a cholesterol-lowering drug (atorvastatin) to the standard combination of two cancer drugs (axitinib and toripalimab) can improve outcomes for people with advanced clear cell kidney cancer that cannot be removed by surgery or has spread. The goal is to see if this three-drug approach is safe and effective.
This trial tests a combination of precise radiation (SBRT) plus two drugs (anlotinib and bimepolizumab) to see if it helps control advanced kidney cancer. The goal is to shrink tumors and slow the cancer's growth.
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
Hear when a new Oligometastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.